The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	BMC 2025-01-01
Reeks:	BMC Complementary Medicine and Therapies
Onderwerpen:	Mild cognitive impairment Alzheimer’s disease Cannabidiol Cannabis-based medicine Patient engagement Patient and public involvement
Online toegang:	https://doi.org/10.1186/s12906-025-04753-w

Gelijkaardige items

Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis
door: Ana Pilar Pérez-Acevedo, et al.
Gepubliceerd in: (2020-12-01)

Individualised computerised cognitive training (iCCT) for community-dwelling people with mild cognitive impairment (MCI): results on cognition in the 6-month intervention period of a randomised controlled trial (MCI-CCT study)
door: Elmar Graessel, et al.
Gepubliceerd in: (2024-10-01)

3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract
door: Anna Gościniak, et al.
Gepubliceerd in: (2024-11-01)

Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
door: Zackary Montoya, et al.
Gepubliceerd in: (2020-09-01)

El cannabidiol y sus indicaciones en psiquiatría
door: Juan Fernando Muñoz Ramírez
Gepubliceerd in: (2021-03-01)

Co-Dispersion Delivery Systems with Solubilizing Carriers Improving the Solubility and Permeability of Cannabinoids (Cannabidiol, Cannabidiolic Acid, and Cannabichromene) from <i>Cannabis sativa</i> (Henola Variety) Inflorescences
door: Anna Stasiłowicz-Krzemień, et al.
Gepubliceerd in: (2023-09-01)

Predictors of institutionalization in users of day care facilities with mild cognitive impairment to moderate dementia
door: Klara Spiegl, et al.
Gepubliceerd in: (2021-09-01)

Plasma Pharmacokinetics of Cannabidiol Following Oral Administration of Cannabidiol Oil to Dairy Calves
door: Kelsey Meyer, et al.
Gepubliceerd in: (2022-01-01)

Reasons for using cannabidiol: a cross-sectional study of French cannabidiol users
door: Davide Fortin, et al.
Gepubliceerd in: (2021-10-01)

Cannabidiol use and perceptions in France: a national survey
door: Clémence Casanova, et al.
Gepubliceerd in: (2022-08-01)

Pharmacovigilance on cannabidiol as an antiepileptic agent
door: Ilaria Ammendolia, et al.
Gepubliceerd in: (2023-02-01)

Patterns of cannabidiol use among marijuana users in the United States
door: Ji-Yeun Park
Gepubliceerd in: (2025-02-01)

The Effects of Cannabidiol on the Driving Performance of Healthy Adults: A Pilot RCT
door: Toni Marie Rudisill, MS, PhD, et al.
Gepubliceerd in: (2023-03-01)

Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases?
door: Milena de Barros Viana, et al.
Gepubliceerd in: (2022-11-01)

Cannabidiol Content and In Vitro Biological Activities of Commercial Cannabidiol Oils and Hemp Seed Oils
door: Masashi Kitamura, et al.
Gepubliceerd in: (2020-09-01)

Effects of Cannabidiol on Locomotor Activity
door: Fabrizio Calapai, et al.
Gepubliceerd in: (2022-04-01)

A Balanced Approach for Cannabidiol Use in Chronic Pain
door: Donovan A. Argueta, et al.
Gepubliceerd in: (2020-04-01)

Comparative Metabolomic Profiling of the Metabolic Differences of Δ9-Tetrahydrocannabinol and Cannabidiol
door: Qianru Rao, et al.
Gepubliceerd in: (2022-11-01)

Current state of knowledge on the use of cannabidiol (CBD) in various medical conditions
door: Zuzanna Lubczyńska, et al.
Gepubliceerd in: (2023-06-01)

In Vitro Evidence of Selective Pro-Apoptotic Action of the Pure Cannabidiol and Cannabidiol-Rich Extract
door: Paweł Śledziński, et al.
Gepubliceerd in: (2023-12-01)

Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs
door: Sasithorn Limsuwan, et al.
Gepubliceerd in: (2024-04-01)

Isolation, Purification, and Antimicrobial Characterization of Cannabidiolic Acid and Cannabidiol from <i>Cannabis sativa</i> L.
door: Laura Daniela Martinenghi, et al.
Gepubliceerd in: (2020-06-01)

Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers
door: Marco Antonio Zenone, et al.
Gepubliceerd in: (2021-07-01)

Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients’ Perspectives and Attitudes
door: Schilling JM, et al.
Gepubliceerd in: (2021-05-01)

Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis
door: Francesco Paolo Busardò, et al.
Gepubliceerd in: (2021-01-01)

Acceptability of and attitudes to the therapeutic use of cannabis and cannabidiol in people with Parkinson’s disease: A French survey
door: Tangui Barré, et al.
Gepubliceerd in: (2024-01-01)

Combinations of Cannabidiol and Δ<sup>9</sup>-Tetrahydrocannabinol in Reducing Chemotherapeutic Induced Neuropathic Pain
door: Diana E. Sepulveda, et al.
Gepubliceerd in: (2022-10-01)

Total cannabidiol (CBD) concentrations and yields from traditional extraction methods: Percolation vs. maceration
door: Jason Wilson, et al.
Gepubliceerd in: (2022-10-01)

Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists
door: Gniewko Wieckiewicz, et al.
Gepubliceerd in: (2022-03-01)

Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity
door: Swapnali Chetia, et al.
Gepubliceerd in: (2020-08-01)

Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression
door: Zsolt Gáll, et al.
Gepubliceerd in: (2020-05-01)

Cannabis Effects on Driving Performance: Clinical Considerations
door: Brianna Costales, et al.
Gepubliceerd in: (2023-01-01)

Production of Cannabidiol Acid Synthase by Chassis Pichia pastoris and of Its Catalytic Activity Analysis
door: Tingli NIU, et al.
Gepubliceerd in: (2023-10-01)

What are the informational pathways that shape people’s use of cannabidiol for medical purposes?
door: Marco A. Zenone, et al.
Gepubliceerd in: (2021-05-01)

A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol
door: Anjali K. Bhardwaj, et al.
Gepubliceerd in: (2024-03-01)

The Potential of Cannabidiol for Treating Canine Atopic Dermatitis
door: Ana F. Bizarro, et al.
Gepubliceerd in: (2025-02-01)

The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects
door: John S. Markowitz, et al.
Gepubliceerd in: (2022-11-01)

Safety assessment of female sexual hygiene product containing cannabidiol in new zealand white rabbit and clinical trial
door: Atiwut Kamudhamas, et al.
Gepubliceerd in: (2024-12-01)

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age
door: José A. Crippa, et al.
Gepubliceerd in: (2018-09-01)

Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?
door: Luisa Rocha, et al.
Gepubliceerd in: (2020-03-01)